share_log

Johnson & Johnson | ARS: Annual Report to Security Holders

Johnson & Johnson | ARS: Annual Report to Security Holders

強生 | ARS：年度報告
SEC announcement ·  03/13 19:45
牛牛AI助理已提取核心訊息
Johnson & Johnson (J&J) experienced a transformative year in 2023, marked by strategic growth and innovation. The company, led by Chairman Joaquin Duato, focused on its core sectors of Innovative Medicine and MedTech. Despite facing litigation and market challenges, J&J reported a 6.5% increase in worldwide sales, reaching $85.2 billion. The growth was partly attributed to the successful separation of its Consumer Health business, now operating as Kenvue, which completed an IPO and an exchange offer, resulting in J&J retaining a 9.5% stake. The company also faced significant legal proceedings, including those related to talc product liabilities, with a reserve of approximately $9 billion established for settlements. J&J's commitment to innovation was evident in its R&D investments, totaling $15.1 billion, and the acquisition of Ambrx Biopharma, Inc. for $2.0 billion. The company's financial position remained strong, with cash and cash equivalents of $21.9 billion and a net debt position of $6.4 billion by year-end.
Johnson & Johnson (J&J) experienced a transformative year in 2023, marked by strategic growth and innovation. The company, led by Chairman Joaquin Duato, focused on its core sectors of Innovative Medicine and MedTech. Despite facing litigation and market challenges, J&J reported a 6.5% increase in worldwide sales, reaching $85.2 billion. The growth was partly attributed to the successful separation of its Consumer Health business, now operating as Kenvue, which completed an IPO and an exchange offer, resulting in J&J retaining a 9.5% stake. The company also faced significant legal proceedings, including those related to talc product liabilities, with a reserve of approximately $9 billion established for settlements. J&J's commitment to innovation was evident in its R&D investments, totaling $15.1 billion, and the acquisition of Ambrx Biopharma, Inc. for $2.0 billion. The company's financial position remained strong, with cash and cash equivalents of $21.9 billion and a net debt position of $6.4 billion by year-end.
強生（J&J）在2023年經歷了變革性的一年，其標誌是戰略增長和創新。該公司由董事長華金·杜阿托領導，專注於創新醫學和醫療科技等核心領域。儘管面臨訴訟和市場挑戰，但強生報告稱，全球銷售額增長了6.5％，達到852億美元。增長部分歸因於其消費者健康業務的成功分離，該業務現在以Kenvue的名義運營，該業務完成了首次公開募股和交易所要約，導致強生保留了9.5％的股份。該公司還面臨重大法律訴訟，包括與滑石產品負債有關的訴訟，爲和解設立了約90億美元的準備金。強生對創新的承諾體現在其研發投資中，總額爲151億美元，以及以20億美元收購Ambrx Biopharma, Inc.該公司的財務狀況仍然強勁，截至年底，現金及現金等價物爲219億美元，淨負債狀況爲64億美元。
強生（J&J）在2023年經歷了變革性的一年，其標誌是戰略增長和創新。該公司由董事長華金·杜阿托領導，專注於創新醫學和醫療科技等核心領域。儘管面臨訴訟和市場挑戰，但強生報告稱，全球銷售額增長了6.5％，達到852億美元。增長部分歸因於其消費者健康業務的成功分離，該業務現在以Kenvue的名義運營，該業務完成了首次公開募股和交易所要約，導致強生保留了9.5％的股份。該公司還面臨重大法律訴訟，包括與滑石產品負債有關的訴訟，爲和解設立了約90億美元的準備金。強生對創新的承諾體現在其研發投資中，總額爲151億美元，以及以20億美元收購Ambrx Biopharma, Inc.該公司的財務狀況仍然強勁，截至年底，現金及現金等價物爲219億美元，淨負債狀況爲64億美元。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。